Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 411-280-2 | CAS number: 74091-64-8 MR-8A; MR-N2; NBDI
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- August 28, 1990 - August 12, 1991
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: This study meets the standards of the EC-method and was conducted according to GLP principles. However, deviations from the test guideline were noted, which affect the reliability of the study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: The Japanese Guidelines for Screening Toxicity Testings of Chemicals (1986)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- no full histopathology was done
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2,5-bis-isocyanatomethyl-bicyclo[2.2.1]heptane
- EC Number:
- 411-280-2
- EC Name:
- 2,5-bis-isocyanatomethyl-bicyclo[2.2.1]heptane
- Cas Number:
- 74091-64-8
- Molecular formula:
- C11H14N2O2
- IUPAC Name:
- (1R,2R,4R,5R)-2,5-bis(isocyanatomethyl)bicyclo[2.2.1]heptane; (1R,2S,4R,5S)-2,5-bis(isocyanatomethyl)bicyclo[2.2.1]heptane; (1S,2R,4S,5R)-2,5-bis(isocyanatomethyl)bicyclo[2.2.1]heptane; (1S,2S,4S,5S)-2,5-bis(isocyanatomethyl)bicyclo[2.2.1]heptane; bis((1r,2R,4s,6S)-2,6-bis(isocyanatomethyl)bicyclo[2.2.1]heptane); bis((1s,2R,4r,6S)-2,6-bis(isocyanatomethyl)bicyclo[2.2.1]heptane)
- Details on test material:
- - Name of test material (as cited in study report): NBDI (BCHI is used in the tables)
- Physical state: liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan
- Age at study initiation: At the start of the exposure, the rats are 5 weeks old.
- Weight at study initiation: males: 157-188, females: 123-151
- Housing: Two rats of the same sex were housed in a polycarbonate cage with hard wood chip bedding
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 5-7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-25 °C
- Humidity (%): 40-70%
- Air changes (per hr): 12 changes/hour
- Photoperiod (hrs dark / hrs light): 12/12 hours
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test substance solutions were prepared by dissolving the test substance in the vehicle (olive oil) at desired concentrations using an ultra high speed homogenizer. The test substance solutions were prepared once a week and stored in the refridgerator until just before use. The stability of the test substance solutions for 7 days after preparation was confirmed by chemical analysis.
VEHICLE
- Amount of vehicle (if gavage): 1.0 ml per 100 g body weight in all rats - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The stability of the test substance solutions for 7 days after preparation was confirmed by chemical analysis. No results included in the report.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once a day in the morning
Doses / concentrationsopen allclose all
- Dose / conc.:
- 15 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Main study:
0 and 500 mg/kg bw/day : 12 (6 for 14-day recovery)
15 and 100 mg/kg bw/day: 6
Additional study:
0, 2, 10 mg/kg bw/day: 6 females
2 mg/kg bw/day: 6 female
10 mg/kg bw/day: 6 female - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: A 1-week preliminary study was performed at the doses of 60, 500 and 700 mg/kg bw/day. It was found that the substance produced toxic effects on animals of the 500 and 700 mg/kg bw/day dose groups. Suppressed body weight gains, thickening of the forestomach and decreased spleen weight.
- Rationale for animal assignment (if not random): so that the body weights in each group became almost the same
- Rationale for selecting satellite groups: to evaluate recovery. Satelite animals in the control and the top dose group
- Post-exposure recovery period in satellite groups: 14 days
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No data
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least once daily, and with palpation once a week
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each cage (two animals) determined and mean daily diet consumption calculated as g food/animal/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data:No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: just before necropsy
- Anaesthetic used for blood collection: Yes (pentobarbital)
- Animals fasted: No data
- How many animals: all
- Parameters were examined: erytrocyte count, Leucocyte count, platelet count, hemoglobin concentration, hematocrit, leucocyte count differential, reticulocyte count, prothrombin time, activated partial thromboplastin time, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: just before necropsy
- Animals fasted: No data
- How many animals: all
- Parameters were examined: total protein, albumin, A/G ratio, Glucose, triglyceride, total cholesterol, urea nitrogen, creatinine, calcium, inorganic phosphorus, GOT(AST), GTP(ALT, gamma-GTP, ALP, sodium, potassium, chloride.
URINALYSIS: Yes
- Time schedule for collection of urine: two days before necropsy
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
- Parameters were examined: pH, occult blood, protein, glucose, ketone bodies, bilirubin, urobilinogen
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes , brain, pituitary, eyes(with Hardian glands), lungs, stomach, thyroids (with parathyroids), heart, liver, spleen, kidneys, adrenals, urinary bladder and bone marrow (femur), testes or ovaries. Of all organs removed at the end of treatment, the heart, liver, kidneys, adrenals, spleen and stomach from rats of both sexes of the control and high dose group and the kidneys from 1 male rat of the low dose group, were examined microscopically. The OECD guideline states that full histopathology should be done. - Statistics:
- Barlett's test.
Anova and dunnett's multiplerange test or Kruskal-Wallis and Dunnet's type rank sum test.
Armitage's chi2test was used for urunary paper tests
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Almost all rats of both sexes of the 500 mg/kg bw/day dose group had salivation after administration continuously after 5 days of treatment (reversible). Although related to the substance, it was only slight and readily improved, disappearing after discontinuation. Some male rats also had soft faeces, reduced spontaneous movement and rales. These symptoms were transient and seemed to be slight.
- Mortality:
- no mortality observed
- Description (incidence):
- No death occurred during the periods of treatment and recovery.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Body weight gains were suppressed in male rats of the 500 mg/kg bw/day dose group during treatment and recovery (up to 13% on day 7 and day 28).
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Decreased in rats of both sexes of the high dose group early in treatment, returned to normal or tended to increase thereafter, and thus considered only slight.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Starting at the 15 mg/kg bw/day dose group, the hematocrit values decreased in the female animals:
At 15 mg/kg bw/day: 5% decrease compared to control
At 100 mg/kg bw/day: 4.8% decrease compared to control
At 500 mg/kg bw/day: 6.4% decrease compared to control
These changes, although statistically significant, are not considered toxicologically relevant, since the decrease is not dose-dependent and only minor. The author of the report considers the effects to be related to the substance. - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At highest dose, increase in GPT in rats of both sexes, increase in GOT in males, decrease in glucose and increase in A/G ratio in female rats.
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Presence of occult blood in male rats of high dose group and decreased protein in female rats of the high dose dose group. These effecst were not considered to be toxicologically relevant.
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant observations:
Female rats of 500 mg/kg bw/day dose group showed an increase of absolute (12%) and relative (7%) liver weights as well as a reduction in relative (14%) and absolute (18%) ovary weight, and decreased relative and absolute adrenal weight. The latter was also seen in the low dose groups (small change and not dose related). Male rats of 500 mg/kg bw/day dose group showed a statistically significant but very slight decrease in absolute liver weight only (2%). - Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In female rats of the high dose group, deposition of glycogen in the liver (6/6) was seen.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on an increase of liver weights and a reduction in ovary weights in the females and a suppression of body weight gain in males at 500 mg/kg bw/day.
Target system / organ toxicity
open allclose all
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- System:
- hepatobiliary
- Organ:
- liver
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- System:
- female reproductive system
- Organ:
- ovary
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
Any other information on results incl. tables
In the additional study with 0, 2 and 10 mg/kg bw/day dose groups, no mortality, no clinical signs, no effect on bodyweight and food consumption, neither on haematological parameters, organ weight and macroscopic examination were observed.
Based on the main study, the effects on organ weights at the highest dose tested and the decrease in body weight gain are considered toxicologically relevant. As all other effects, clinical signs, haematological and biochemical effects, are considered not relevant, the NOAEL is considered to be 100 mg/kg bw/day. Note: no microscopic examination of several organs was performed, therefore the organ weight effects although sometimes slight, are considered relevant.
Applicant's summary and conclusion
- Conclusions:
- In a sub-acute oral study in rats a NOAEL (systemic effects) of 100 mg/kg bw/day was established based on an increase of liver weights and a reduction in ovary weights in the females and a suppression of body weight gain in males at 500 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.